Research progress of HGF/c-Met signaling pathway in oral squamous cell carcinoma

Research progress of HGF/c-Met signaling pathway in oral squamous cell carcinoma

Oral squamous cell carcinoma (OSCC) is a malignant tumor that seriously threatens human health. Its typical biological characteristics include strong local invasiveness, high lymph node metastasis rate, and high recurrence rate after treatment. Hepatocyte growth factor (HGF), cellular-mesenchymal to...

Full description

Saved in:

Bibliographic Details
Main Author:	SHI Jiafan, GONG Lingling, SUN Mingze, LIU Lulu, ZHANG Huilin, LI Ming
Format:	Article
Language:	zho
Published:	Editorial Department of Journal of Prevention and Treatment for Stomatological Diseases 2025-08-01
Series:	口腔疾病防治
Subjects:	oral squamous cell carcinoma\|hepatocyte growth factor\|cellular-mesenchymal to epithelial transition factor\|mechanism\|phosphatidylinositide 3-kinases\|protein kinases b\|epidermal growth factor receptor\|targeted therapy\|monoclonal antibodies\|tyrosine kinase inhibitor
Online Access:	https://www.kqjbfz.com/fileup/2096-1456/PDF/1754449152045-978652041.pdf
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Gefitinib-induced skin ulceration in metastatic adenocarcinoma lung
by: Vishwanath Sathyanarayanan, et al.
Published: (2014-01-01)

Perturbation of the mutated EGFR interactome identifies vulnerabilities and resistance mechanisms
by: Jiannong Li, et al.
Published: (2013-11-01)

ARID1A deficiency attenuates the response to EGFR-TKI treatment in lung adenocarcinoma
by: Fangfang Yang, et al.
Published: (2025-05-01)

Real-world analysis of survival outcomes in advanced EGFR-mutant NSCLC patients treated with platinum-pemetrexed after EGFR-TKI treatment failure
by: Zong-Han Yao, et al.
Published: (2025-08-01)

Chromosomal Instability Is Associated with cGAS–STING Activation in EGFR-TKI Refractory Non-Small-Cell Lung Cancer
by: Kimio Yonesaka, et al.
Published: (2025-03-01)

Afatinib Combined with Bevacizumab in the Treatment of Patients with Non-Small Cell Lung Cancer Harboring EGFR G719X, S768I or L861Q/P Mutations
by: Han X, et al.
Published: (2024-11-01)

The Difficulties of Differential Diagnosis of the Bronchial Obstruction Syndrome
by: I. V. Demko, et al.
Published: (2021-08-01)

Iparomlimab and tuvonralimab (QL1706) plus chemotherapy and bevacizumab for EGFR-mutant patients with advanced non-small cell lung cancer after failure of EGFR-tyrosine kinase inhibitors: updated results from cohort 5 in the DUBHE-L-201 study
by: Yaxiong Zhang, et al.
Published: (2025-07-01)

The Role of Plant-Derived Natural Products as a Regulator of the Tyrosine Kinase Pathway in the Management of Lung Cancer
by: Faris Alrumaihi, et al.
Published: (2025-06-01)

The expression and clinical significance of PTK7 in oral squamous cell carcinoma
by: JIA Guodong, et al.
Published: (2023-04-01)

A pharmacovigilance study of thromboembolism events associated with vascular endothelial growth factor receptor tyrosine kinase inhibitors based on FAERS database
by: Zongwei Tang, et al.
Published: (2025-07-01)

Mesenchymal stem cell-derived exosomes improve vascular remodeling by inhibiting EGFR/ErbB2 heterodimerization in hypoxic pulmonary hypertension
by: Yao-Xin Chen, et al.
Published: (2025-07-01)

Palmitoylation Transduces the Regulation of Epidermal Growth Factor to Organic Anion Transporter 3
by: Zhou Yu, et al.
Published: (2025-06-01)

Luteolin attenuates inflammation and apoptosis in LPS-induced ALI mice by activating the HGF/c-Met pathway
by: Jihong Bi, et al.
Published: (2025-07-01)

A molecular dynamics protocol for rapid prediction of EGFR overactivation and its application to the rare mutations S768I, S768N, D761N
by: Julian Behn, et al.
Published: (2025-01-01)

The mechanisms of acquired resistance to anti-EGFR drugs in non-small cell lung cancer not associated with T790m mutation and their significance in clinical practice
by: E. V. Karabina, et al.
Published: (2018-11-01)

Large‐scale phosphorylation mapping reveals the extent of tyrosine phosphorylation in Arabidopsis
by: Naoyuki Sugiyama, et al.
Published: (2008-05-01)

Advances and controversies in new techniques of breast pathology
by: ZHANG Yujia, MA Li
Published: (2025-03-01)

Research progress on cell cycle regulation-related molecules in the development of oral squamous cell carcinoma
by: HOU Zeyu, et al.
Published: (2023-04-01)

Diagnostic value of sFlt‐1/PlGF‐1 ratio and plasma PROK1 for adverse pregnancy outcomes in women with hypertensive disease of pregnancy
by: Ping Lv, et al.
Published: (2024-12-01)

Reversible hypopigmentation with pazopanib
by: B J Srinivasa, et al.
Published: (2018-01-01)

HGF Aggravated Periodontitis-Associated Gut Barrier and Microbial Dysfunction: Implications for Oral–Gut Axis Regulation
by: Zhen Chen, et al.
Published: (2025-05-01)

How to treat a patient with psoriatic arthritis and chronic lymphocytic leukemia?
by: Jürgen Braun, et al.
Published: (2024-06-01)

The roles, signalling pathways and therapeutic implications of Apoc1 in cancer
by: Hao-Han Guo, et al.
Published: (2025-05-01)

Pathogenetic Approach to Early Preeclampsia and the Feasibility of Pregnancy Prolongation
by: L. D. Belotserkovtseva, et al.
Published: (2022-04-01)

8-Nitrotryptanthrin inhibits colorectal cancer progression via TGF-β/SMAD and PI3K/AKT/mTOR pathways
by: Cheng-Yu Sun, et al.
Published: (2025-08-01)

New approaches in 3D modeling of in vitro growth of primary cultures of malignant gliomas
by: Yu. A. Khochenkova, et al.
Published: (2019-12-01)

ROS1 Expression Correlates With Inguinal Lymph Node Affection in Vulvar Cancer Patients: A Retrospective Study
by: Meletios P. Nigdelis, et al.
Published: (2025-08-01)

Clinico-radiological and pathological characteristics of inflammatory myofibroblastic tumors in children: A retrospective study
by: Mohamad Hussain Mir, et al.
Published: (2017-01-01)

AXL and SRC in clear cell renal cell carcinoma: absence of mutations, rare alternative splicing events, but association of protein expression with poor prognosis
by: Muriel D Brada, et al.
Published: (2025-05-01)

Disseminated medullary thyroid carcinoma. Optimal approach to treatment
by: I. S. Romanov, et al.
Published: (2019-01-01)

Uveal melanoma following Bruton's tyrosine inhibitor use for the treatment of hematologic malignancies
by: Tara Murty, et al.
Published: (2025-06-01)

Targeted Therapy in a Rare Spindle Cell Tumor with <i>ETV6-NTRK3</i> Gene Fusion Rearrangement: A Case Report
by: Jessé Lopes da Silva, et al.
Published: (2025-01-01)

Vasotoxic Effects of Anticancer Therapy: a Review of Current Data
by: Yu. A. Vasyuk, et al.
Published: (2023-05-01)

Brain-derived neurotrophic factor and neurotrophic tyrosine receptor kinase-2 in stallion testes: insights into seasonal changes and potential roles in spermatogenesis
by: Muhammad Shakeel, et al.
Published: (2025-07-01)

Immunomodulatory role of spleen tyrosine kinase in chronic inflammatory and autoimmune diseases
by: Yaqi Zhou, et al.
Published: (2023-07-01)

Combination of Osimertinib and Brigatinib in the Treatment of EGFR Triple-Mutated Lung Adenocarcinoma: A Case Report
by: Daphnée Demers, et al.
Published: (2025-05-01)

Ligand‐dependent responses of the ErbB signaling network: experimental and modeling analyses
by: Marc R Birtwistle, et al.
Published: (2007-11-01)

Upfront Management of Blastoid Variant Mantle Cell Lymphoma: Making the Case for 2nd/3rd‐Generation Bruton Tyrosine Kinase Inhibitor‐Based Therapies
by: Benjamin J. Lee, et al.
Published: (2024-10-01)

Epidermal Growth factor in human urine as promotor for the growth of Leishmania sp. In vitro.
by: Nuha S. Al-Bayatii, et al.
Published: (2023-02-01)